Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study

Completed · Not applicable

Conditions studied: BRCA1/2 Negative

In brief

The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.

Key facts

Study ID

NCT02514499

Run by

Abramson Cancer Center at Penn Medicine

People needed

350

Starts

2014-07-01

Expected to finish

2018-10-01

Last updated by the study team

2019-07-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Women and men (at least 18 YO) 2. English speaking AND 3. Negative for BRCA1 and BRCA2 mutations

You may not qualify if…

• Non English speaking patients

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.